Show simple item record

dc.contributor.authorBrown, Daniel V
dc.contributor.authorDaniel, Paul M
dc.contributor.authorD'Abaco, Giovanna M
dc.contributor.authorGogos, Andrew
dc.contributor.authorNg, Wayne
dc.contributor.authorMorokoff, Andrew P
dc.contributor.authorMantamadiotis, Theo
dc.date.accessioned2020-02-17T02:45:10Z
dc.date.available2020-02-17T02:45:10Z
dc.date.issued2015
dc.identifier.issn1949-2553
dc.identifier.doi10.18632/oncotarget.3365
dc.identifier.urihttp://hdl.handle.net/10072/391563
dc.description.abstractAccumulating evidence suggests that the stem cell markers CD133 and CD44 indicate molecular subtype in Glioblastoma Multiforme (GBM). Gene coexpression analysis of The Cancer Genome Atlas GBM dataset was undertaken to compare markers of the Glioblastoma Stem-Progenitor Cell (GSPC) phenotype. Pearson correlation identified genes coexpressed with stem cell markers, which were then used to build a gene signature that classifies patients based on a CD133 coexpression module signature (CD133-M) or CD44-M subtype. CD133-M tumors were enriched for the Proneural (PN) GBM subtype compared to Mesenchymal (MES) subtype for CD44-M tumors. Gene set enrichment identified DNA replication/cell cycle genes in the CD133-M and invasion/migration in CD44-M, while functional experiments showed enhanced cellular growth in CD133 expressing cells and enhanced invasion in cells expressing CD44. As with the 4 major molecular subtypes of GBM, there was no long-term survival difference between CD44-M and CD133-M patients, although CD44-M patients responded better to temozolomide while CD133-M patients benefited from radiotherapy. The use of a targeted coexpression approach to predict functional properties of surface marker expressing cells is novel, and in the context of GBM, supports accumulating evidence that CD133 and CD44 protein marker expression correlates with molecular subtype.
dc.description.peerreviewedYes
dc.languageEnglish
dc.language.isoeng
dc.publisherImpact Journals, LLC
dc.relation.ispartofpagefrom6267
dc.relation.ispartofpageto6280
dc.relation.ispartofissue8
dc.relation.ispartofjournalOncotarget
dc.relation.ispartofvolume6
dc.subject.fieldofresearchOncology and Carcinogenesis
dc.subject.fieldofresearchcode1112
dc.subject.keywordsScience & Technology
dc.subject.keywordsLife Sciences & Biomedicine
dc.subject.keywordsOncology
dc.subject.keywordsCell Biology
dc.subject.keywordscoexpression
dc.titleCoexpression analysis of CD133 and CD44 identifies Proneural and Mesenchymal subtypes of glioblastoma multiforme
dc.typeJournal article
dc.type.descriptionC1 - Articles
dcterms.bibliographicCitationBrown, DV; Daniel, PM; D'Abaco, GM; Gogos, A; Ng, W; Morokoff, AP; Mantamadiotis, T, Coexpression analysis of CD133 and CD44 identifies Proneural and Mesenchymal subtypes of glioblastoma multiforme, Oncotarget, 2015, 6 (8), pp. 6267-6280
dcterms.dateAccepted2015-01-12
dcterms.licensehttp://creativecommons.org/licenses/by/3.0/
dc.date.updated2020-02-17T02:43:15Z
dc.description.versionVersion of Record (VoR)
gro.rights.copyright© 2015 Brown et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License 3.0 (CC BY 3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
gro.hasfulltextFull Text
gro.griffith.authorNg, Wayne


Files in this item

This item appears in the following Collection(s)

  • Journal articles
    Contains articles published by Griffith authors in scholarly journals.

Show simple item record